PDGFRB and neoplasm: Pazopanib is a novel multitarget TKI that targets VEGFR-1, VEGFR-2, VEGFR-3, PDGFR/β, and c-Kit, and has been shown to inhibit tumor growth and angiogenesis in in vitro studies [77].